Entity

Time filter

Source Type

South San Francisco, CA, United States

Krabben A.,Leiden University | Knevel R.,Leiden University | Huizinga T.W.J.,Leiden University | Cavet G.,Crescendo Bioscience | Van Der Helm-Van Mil A.H.M.,Leiden University
Journal of Rheumatology | Year: 2013

Objective. Previous studies indicated that pyridinoline, a collagen crosslink in cartilage and bone, might be a good marker to predict joint destruction in patients with rheumatoid arthritis (RA), although large prospective studies are lacking. We evaluated the predictive value of serum pyridinoline levels for joint destruction, both at baseline for longterm prediction and during the disease course for near-term prediction. Methods. Patients with early RA from the Leiden Early Arthritis Clinic were studied. Radiographs at baseline and yearly during 7 years of followup were scored according to the Sharp-van der Heijde Scoring (SHS) method. Pyridinoline serum levels at baseline and during followup were measured by ELISA. The association between baseline pyridinoline levels and difference in SHS over 7 years was tested, with a multivariate normal regression model. Second, the association between pyridinoline levels determined during the disease course and progression of SHS over the next year was tested with a multivariable linear regression analysis. Results. Studying baseline pyridinoline serum levels in 437 patients revealed that the mean SHS over 7 years was 6% higher for every higher pyridinoline level (nmol/l) at baseline (p = 0.001). Subsequently, during followup (n = 184 patients) the progression in SHS in the upcoming year was 17% higher for every higher nmol/l pyridinoline level (p = 0.001). The area under the receiver-operation characteristic curve for rapid radiological progression was 0.59. Conclusion. Increased pyridinoline serum levels, both at baseline and during the disease course, are associated with more severe joint destruction during the coming year(s), although the predictive accuracy as a sole predictor was moderate. Copyright © The Journal of Rheumatology 2013.


Patent
Crescendo Bioscience and Oklahoma Medical Research Foundation | Date: 2015-08-21

Biomarkers useful for diagnosing and assessing inflammatory disease are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. The biomarkers include at least two biomarkers selected from the DAIMRK group and the score is a disease activity index (DAI).


Patent
Crescendo Bioscience and Oklahoma Medical Research Foundation | Date: 2010-10-15

Biomarkers useful for diagnosing and assessing inflammatory disease are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. The biomarkers include at least two biomarkers selected from the DAIMRK group and the score is a disease activity index (DAI).


Patent
Oklahoma Medical Research Foundation and Crescendo Bioscience | Date: 2011-11-07

A method scores a sample, by receiving a first dataset associated with a first sample obtained from a first subject, wherein said first dataset comprises quantitative data for at least two markers selected from the group consisting of: CCL22; CHI3L1; COMP; CRP; CSF1; CXCL10; EGF; ICAM1; ICAM3; ICTP; IL1B; IL2RA; IL6; IL6R; IL8; LEP; MMP1; MMP3; PYD; RETN; SAA1; THBD; TIMP1; TNFRSF11B; TNFRSF1A; TNFSF11; VCAM1; and VEGFA; and determining a first SDI score from said first dataset using an interpretation function, wherein the first SDI score provides a quantitative measure of the rate of change in joint structural damage in said first subject.


BOSTON & SAN FRANCISCO--(BUSINESS WIRE)--LEERINK Capital Partners, the asset management affiliate of LEERINK Partners, a leading healthcare investment bank, and Revelation Partners, an investment firm focused on late-stage, private healthcare companies, announced today that they have created an investment platform that provides capital and liquidity to healthcare investors, companies, founders and funds, called LEERINK Revelation Partners. In addition, they announced the close of its first fund, LEERINK Revelation Healthcare Fund I, with $192 million of commitments, surpassing its initial target of $175 million. LEERINK Revelation Partners combines the experience and resources of LEERINK’s leading healthcare investment bank with Revelation Partners’ established leadership in secondary transactions across healthcare. The investing team is based in San Francisco and invests broadly across healthcare sectors, focusing on commercial companies that have proven business models or companies with novel technologies that have clear clinical and regulatory pathways. Specifically, the firm invests in medical devices, diagnostics, biopharmaceuticals, healthcare IT and healthcare services. Recent investments of the Fund include: Crescendo Bioscience, PneumRX, Inc., Corventis and DiscoveRx Corporation. The investment team, led by Scott Halsted, Dr. Zack Scott, and Michael Boggs has been executing this strategy, often referred to as direct secondary investing, for the past seven years. Prior to the partnership with LEERINK, the investment team has invested over $230 million in healthcare secondary transactions. Jeff Leerink, Chairman and CEO of LEERINK Partners, said, "We are very excited by this partnership and look forward to working with Scott and his team. Our unique position and institutional knowledge in the healthcare marketplace will help to strengthen what is already a very impressive team and investment platform, and we are all equally committed to its success.” James Nahirny, Managing Partner of LEERINK Capital Partners said, “We see this as yet another way in which LEERINK can support companies and investors who are shaping the future of healthcare. Revelation Partners’ substantial experience and proven track record in direct secondary investing in late-stage, private healthcare companies makes them an ideal partner for LEERINK, as we are uniquely suited to add value to this highly regarded investment team.” “We believe our investment strategy capitalizes on an attractive market opportunity, given the macro trends affecting traditional healthcare investors and declining number of active venture capital firms,” said Mr. Halsted. “There are many exciting healthcare companies that have taken more time and more money than originally expected to achieve scale and, as a result, there is often misalignment in the investor syndicate relative to the ability or desire to fund the company for an optimal exit. By providing liquidity and financing options to these existing investors, we can help to re-align the investors and maximize the company’s value.” He continued, “Working with LEERINK provides a substantial competitive advantage, and we look forward to leveraging their distinct expertise, broad industry relationships and unrivaled position in healthcare to deliver value to our investors and portfolio companies alike.” LEERINK Partners LLC is a leading investment bank, specializing in healthcare. Our knowledge, experience and focus enable us to help our clients define and achieve their strategic, capital markets and investment objectives. We partner with companies that develop and commercialize innovative products and services that are defining the future of healthcare. LEERINK Partners LLC is a member of FINRA/SIPC. For more information, please visit: www.leerink.com. Revelation Partners is a San Francisco-based investment firm that invests in late-stage, private healthcare companies acquired in negotiated transactions from existing shareholders. We invest broadly across healthcare sectors with a focus on commercial companies with proven business models or companies with novel technologies that have clear clinical and regulatory pathways. We actively invest in the following healthcare verticals - medical devices, biopharmaceuticals, healthcare IT and healthcare services. For more information, please visit: www.revelation-partners.com.

Discover hidden collaborations